Trial Profile
A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Pimodivir (Primary) ; Oseltamivir
- Indications Influenza A virus infections
- Focus Therapeutic Use
- Acronyms Topaz
- Sponsors Johnson & Johnson Innovative Medicine; Vertex Pharmaceuticals
- 14 Nov 2018 Status changed to discontinued as the primary end point of virus load AUC was met during a planned interim analysis as per results published in the Journal of Infectious Diseases
- 14 Nov 2018 Results published in the Journal of Infectious Diseases
- 24 Apr 2018 Results of a pooled analysis from this and one other study, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.